Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein

Abstract excerpt

A major goal of current HIV-1 vaccine design efforts is to induce broadly neutralizing antibodies (bNAbs). The VH1-2-derived bNAb IOMA directed to the CD4-binding site of the HIV-1 envelope glycoprotein is of interest because, unlike the better-known VH1-2-derived VRC01-class bNAbs, it does not require a rare short light chain complementarity-determining region 3 (CDRL3). Here, we describe three IOMA-class NAbs,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glycosylation and Glycoproteins Research
• Share to HIV Research and Treatment
• Share to Monoclonal and Polyclonal Antibodies Research